The haemodynamic effects of GR 32191, a thromboxane A2 receptor antagonist, in patients with renal artery stenosis and hypertension
British Journal of Clinical Pharmacology. 1993; 36(3): 271-273.
This study was designed to determine if GR 32191 a thromboxane A2 receptor antagonist, would lower blood pressure in patients with hypertension and renal artery stenosis. Eight patients with unilateral atheromatous renal artery stenosis and hypertension were studied in a double-blind, single dose, placebo controlled, crossover study. The results show that, GR 32191, given orally, in doses of 20 mg and 40 mg, does not reduce the blood pressure to any clinically important degree
Biphenyl Compounds [Pharmacology]; Blood Pressure [Drug Effects]; Heptanoic Acids [Pharmacology]; Hypertension,Renovascular [Drug Therapy] [Complications]; Receptors,Thromboxane [Antagonists & Inhibitors]; Renal Artery Obstruction [Complications]; Aged; Cross-Over Studies; Dose-Response Relationship,Drug; Double-Blind Method; Hemodynamics [Drug Effects]; Middle Age; Support,Non-U.S Gov't
RCT
Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill
